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Abstract
Background: Bryophyllum pinnata (B. pinnata) is a common medicinal plant used in traditional medicine of India
and of other countries for curing various infections, bowel diseases, healing wounds and other ailments. However,
its anticancer properties are poorly defined. In view of broad spectrum therapeutic potential of B. pinnata we
designed a study to examine anti-cancer and anti-Human Papillomavirus (HPV) activities in its leaf extracts and
tried to isolate its active principle.
Methods: A chloroform extract derived from a bulk of botanically well-characterized pulverized B. pinnata leaves
was separated using column chromatography with step- gradient of petroleum ether and ethyl acetate. Fractions
were characterized for phyto-chemical compounds by TLC, HPTLC and NMR and Biological activity of the fractions
were examined by MTT-based cell viability assay, Electrophoretic Mobility Shift Assay, Northern blotting and assay
of apoptosis related proteins by immunoblotting in human cervical cancer cells.
Results: Results showed presence of growth inhibitory activity in the crude leaf extracts with IC50 at 552 μg/ml which
resolved to fraction F4 (Petroleum Ether: Ethyl Acetate:: 50:50) and showed IC50 at 91 μg/ml. Investigations of anti-viral
activity of the extract and its fraction revealed a specific anti-HPV activity on cervical cancer cells as evidenced by
downregulation of constitutively active AP1 specific DNA binding activity and suppression of oncogenic c-Fos and c-
Jun expression which was accompanied by inhibition of HPV18 transcription. In addition to inhibiting growth, fraction
F4 strongly induced apoptosis as evidenced by an increased expression of the pro-apoptotic protein Bax, suppression
of the anti-apoptotic molecules Bcl-2, and activation of caspase-3 and cleavage of PARP-1. Phytochemical analysis of
fraction F4 by HPTLC and NMR indicated presence of activity that resembled Bryophyllin A.
Conclusions: Our study therefore demonstrates presence of anticancer and anti-HPV an activity in B. pinnata
leaves that can be further exploited as a potential anticancer, anti-HPV therapeutic for treatment of HPV infection
and cervical cancer.
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Background
For many centuries, plants have been a rich source of
therapeutic agents and provided basis for several syn-
thetic drugs. Despite great development of organic
synthesis, currently 75% of prescribed drugs worldwide
are derived from plant sources [1], showing that plant
species are still an important source of new drugs for
diseases that continue to lack a cure, such as cancer.
Bryophyllum pinnatum (Lam.) (synonym: Kalanchoe
pinnata, Lam.; common names: Life plant, air plant
(Mexican), love plant, Canterbury bells, Cathedral bells,
etc) is a perennial herb that grow in the wild and used
as a traditional medicinal plant in tropical Africa, China,
Australia, tropical America and Indian system of medi-
cine- Ayurveda. The leaf extracts of this plant have been
routinely used for ailments like bacterial, fungal and
viral infections, asthma, kidney stones, and ulcers. The
leaves of this plant have been reported to possess
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any medium, provided the original work is properly cited.antimicrobial [2], antifungal [3], anti-ulcer [4], anti-
inflammatory and analgesic [5,6], antihypertensive [7],
antidiabetic [8] and antimutagenic activities [9]. A num-
ber of active compounds, including flavonoids, glyco-
sides, steroids, bufadienolides and organic acids have
been identified in B. pinnata [10-12] that have been
shown individually to possess variety of activities such
as antibacterial, antitumor, cancer preventive and insec-
ticidal actions. The flavonoid glycoside, Quercitrin
(quercetin 3- O- alpha- L-rhamnopyranoside) and skap
innato side were isolated with anti-leishmanial activity
[13-17]. Despite having broad spectrum therapeutic
potential, B. pinnata’s anticancer activity in general and
anti-HPV activity in particular have not been explored
as yet.
Cervical cancer is the principal cause of cancer-related
mortality in women of the developing countries that
contribute more than 85% of global disease burden [18].
Persistent infection with high-risk human papillomavirus
(HR-HPV), most notably of the type 16 and 18, is an
essential prerequisite for the development of cervical
cancer [19-23] resulting in dysregulation of host cell
cycle by targeting pivotal cell cycle proteins p53 & pRb
by their viral gene products E6 & E7, respectively. Con-
stitutive expression of HR-HPV E6 and E7 oncogene is
mainly dependent on the availability of host cell tran-
scription factors that act upon viral promoter and
enhancer region. Activator protein-1 (AP1), a heterodi-
m e ro fag r o u po fs t r u c t u r a l l y and functionally related
members of the Jun (c-Jun, JunB, JunD) and Fos family
(c-Fos, FosB, Fra-1 and Fra-2) is one of the transcription
factors that are essentially required for viral oncogene
expression [24]. Mutational inactivation of AP1 cis-act-
ing site within the HR-HPV upstream regulatory region
(URR) that facilitates AP1 interactions revealed a com-
plete loss of transcriptional activity of the E6/E7 promo-
ter and showed a key role of AP1 in HPV-mediated
carcinogenesis [25]. Studies by our group demonstrated
a significant overexpression of constitutively active AP1
family members in cervical precancer and cancer tissues
[26]. Though HPV-mediated mechanism of cervical car-
c i n o g e n e s i si sn o ww e l ld e f i ned, anti-HPV therapeutics
for elimination of HPV infections are yet to become a
clinical reality and conventional physical ablation of
HPV- infected lesions in precancer stage are in clinical
practice [27]. Currently, there is no HPV specific
advanced therapy for treatment of cervical cancer.
Recent studies have shown that anti-oxidants and herbal
derivatives may be effective against prevailing HR-HPV
infection but these leads are yet to prove their efficacy
in preclinical and subsequent clinical studies [26-29].
In view of absence of anti-HPV therapeutic for pre-
vention and treatment of cervical cancer, in the present
study, we examined leaves of B. pinnata for presence of
anti-cancer and anti-HPV activity against human cervi-
cal cancer cells, HeLa that harbors HR-HPV type 18.
Materials and methods
Materials
The HPV18 positive human cervical cancer cell line,
HeLa was obtained from the American Type Culture
Collection (ATCC), USA. Polyclonal antibodies to Cas-
pase-3, PARP-1, Bax, Bcl-2, b -actin, c-Jun, JunB, JunD,
and c-Fos were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Dulbecco’s modified Eagle’sm e d -
ium (DMEM), Fetal calf serum (FCS), 3-(4, 5-
dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide
(MTT), penicillin-streptomycin solution and all other
reagents used in present study were of analytical grade
and purchased from Sigma (St Louis, MO).
Collection of plant material and identification
The leaves of B. pinnata were collected from Indore
region of Madhya Pradesh (MP), India in the month of
March-April, identified and authenticated by the
Department of Botany, Devi Ahilya Vishwavidyalaya,
I n d o r e ,M a d h y aP r a d e s h ,I n d i a .T h ec o l l e c t e dp l a n t
material was made free from foreign organic matter.
Extraction and separation through column
chromatography
Fresh leaves (20 kg) were crushed, washed with water
and filtered. After filtration, the residual leaf material
was dried and extracted with chloroform (Soxhlet
extraction). The chloroform extract then dried and
designated A. On the other hand, the filtered water was
shaken with chloroform. The chloroform layer then
separated from water layer, dried and designated B.
Finally, both the extract A and B were mixed together
and designated C (26.44 gm). The C was separated
through silica gel column chromatography with the sol-
vent petroleum ether (100-0%) to ethyl acetate (0-100%)
in gradient step and final elution was performed with
100% methanol. Thus resulting in 6 different fractions
that were designated from Fraction F1 to Fraction F6
(Figure 1). Finally fractions were concentrated under
vacuum.
Thin layer chromatographic (TLC) analysis
All the fractions were applied on to the precoated silica
gel TLC plates and chromatographed using the solvent
system chloroform: methanol (95:5). Plates were exam-
ined under UV and visible light as described earlier.
Phytochemical analysis
Specimen from each fraction was examined to check the
presence of bioactive phytochemicals using different
chemical tests. Raymond test was performed for
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Page 2 of 11detecting the presence of steroidal glycosides. Briefly, 0.5
g of the extracts was dissolved in 1 ml of 50% ethanol
and 0.1 ml 1% solution of metadinitrobenzene in metha-
nol. 2-3 drops of 20% sodium hydroxide were added
that lead to violet coloration which changed to blue
with presence of steroidal glycosides. Dragendorff’st e s t
was performed for detecting the presence of alkaloids.
Briefly, 0.5 g of dried extracts was dissolved in methanol
and added with Dragendorff’s reagent. Turbidity and
precipitation indicated the positive test for alkaloids.
Nuclear Magnetic Resonance (NMR) spectroscopy analysis
Specimens from each fraction were subjected to Proton
NMR (Bruker AMX-400 NMR spectrometer). (
1H
N M R )s p e c t r aw e r er e c o r d e di nC D C l 3o n4 0 0M H z .
Chemical shifts are cited in ppm with respect to SiMe4
as an internal control.
High Performance Thin Layer Chromatographic (HPTLC)
analysis
Silica gel 60 F254 (10 cm × 10 cm; 2 mm thickness, E.
Merck, Darmstad, Germany) was used as stationary
phase and extract band (application volume 8 μl, width
8 mm, space between bands 14 mm) was applied on the
plate with CAMAG Micro-liter syringe. Chloroform:
methanol (9.5:0.5 v/v) was used as mobile phase. Cham-
ber was saturated for 15 min at room temperature. The
length of chromatogram run was 85 mm. Plate was
d e v e l o p e df o r9 0m i ni nT w i nt r o u g hg l a s sc h a m b e r
(CAMAG, Muttenz, Switzerland). Densitometric analysis
was done with CAMAG TLC scanner III with scanning
speed of 20 mm/sec at detection wave length of 360 nm
and 615 nm by employing D2 & W lamp as radiation
source and the procedure were operated by winCATS
software (Ver. 1.2.0). Chromatogram recorded on two
modes, first before and then after spraying anisaldehyde-
sulphuric acid (AS) reagent. CAMAG Linomat-V appli-
cation (CAMAG, Muttenz, Switzerland) was used for all
above analysis.
Cell culture
HeLa cells were cultured in DMEM supplemented with
10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin
and maintained at 37°C in a humidified atmosphere of
5% CO2 as recommended by ATCC. B. pinnata was
freshly dissolved in DMSO prior to cell culture treat-
ment and cells were treated with variable concentration
of B. pinnata crude extract and its fractions (F1-F6) and
examined for viability, AP-1 DNA binding activity and
other molecular assays as described.
MTT assay
The cells (1 × 10
3) seeded in 96-well plate and grown
overnight, were treated with crude extract and different
fractions at indicated concentration for 24 h, 48 h and
72 h. Two hours prior to completion of treatment dura-
tion, cultures were supplemented with MTT. After the
incubation at 37°C, the cells were lysed with lysis buffer
containing 50% of dimethyl formamide and 20% SDS
and absorbance was measured at 570 nm using microti-
tre plate reader (Biotek, Winooski, Vermont) as
described earlier [28]. The percentage of cell viability
was calculated using the following formula: Percentage
cell viability = (OD of the experiment samples/OD of
the control) × 100. IC50 was calculated by linear inter-
polation method using the formula: IC50 = [(50-A)/(B-
A ) ]×( D - C )+C ,w h e r eA=t h ef i r s tp o i n to nt h e
curve, expressed in percent inhibition, that is less than
50%; B = the first point on the curve, expressed in per-
cent inhibition, that is greater than or equal to 50%; C =
the concentration of inhibitor that gives A% inhibition;
and D = the concentration of inhibitor that gives B%
inhibition [30].
Isolation of Nuclear Proteins and Electrophoretic mobility
shift assay (EMSA)
Nuclear proteins were isolated from treated and control
HeLa cells and were subjected to EMSA to assess AP1
-specific DNA binding as previously described [28].
Briefly, cells treated with different concentration of
crude extract and fraction F4 for 24 hours were
Bryophyllum pinnata (20 kg fresh leaves)
Homogenized with 2 L of water
Residue Aqueous  phase
shaken with chloroform
Chloroform extract (A) Chloroform extract (B)  Aqueous phase
Crude extract (C)
(Oily residue)    
Silica Gel Column
Chromatography
(5*40cm)
Pet Eth (100%)      Pet Eth : Eth Acet (75:25)    Eth Acet (100%)
(F1) (F3)                               (F5)                     
Pet Eth : Eth Acet (95:5)   Pet Eth : Eth Acet (50:50)   Meth(100%)
(F2)                                    (F4)                           (F6)
Figure 1 Flow chart of extraction and column chromatographic
separation of Bryophyllum pinnata leaves. 20 kg fresh leaves of B.
pinnata were crushed with water and filtered. Residue was dried
and extracted with chloroform and fractionated with gradient of
petroleum ether and ethyl acetated followed by washing with
methanol. Fractions were designated as F1 to F6 as indicated in the
figure. Pet Eth, Petroleum Ether; Eth Acet, Ethyl Acetate; Meth,
Methanol.
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protein concentration of the extracts was measured by
the spectrophotometric method using Nanodrop spec-
trophotometer (ND-1000). For EMSA, 10 μg of nuclear
proteins from each sample were incubate with
32P-
radio labeled oligonucleotide probe containing consen-
sus sequence 5’-CGCTTGATGACTCAGCCGGAA-3’
that binds AP1 proteins. The DNA-protein complexes
were then resolved on 4.5% non-denaturing PAGE,
dried and exposed overnight to Kodak X-Omat Films
(Kodak India Ltd., India). The quantitative densitometric
analysis was performed using Alpha Ease FC version
4.1.0 (Alpha Innotech Corporation, IL). Binding specifi-
city of AP1 probe was checked by using nuclear proteins
of HeLa cells with unlabelled 100x molar excess of cold
specific competitor (AP1) and non-specific competitor
(Oct-1; 5’-TGTCGAATGCAAATCACTAGAA- 3’).
Isolation of whole cell protein and immunoblotting
Whole-cell proteins were isolated as described earlier
[28] and protein concentration was determined using
Nanodrop spectrophotometer (ND-1000). For immuno-
blotting, 50 μg/ml of cellular protein/lane was separated
on 10% SDS-PAGE and electrotransferred to Immobilin-
P membranes (Millipore Corporation, Bedford, MA).
Blots were blocked with 5% non-fat milk in PBS con-
taining 0.05% Tween (PBST), rinsed in PBST and incu-
bated overnight at 4°C with the indicated primary
antibodies in PBST containing 5% milk. Blots were
again washed in PBST and further incubated with HRP-
conjugated secondary antibody (Santa Cruz Biotech
USA). The bands were visualized using the Luminol
reagent detection kit (Santa Cruz Biotech, USA) and
exposed to autoradiography film (Kodak). The western
blot membranes were re- probed for b- actin expression
as an internal control. The quantitative densitometric
analysis of the bands was performed using Alpha Ease
FC version 4.1.0 (Alpha Innotech Corporation, IL). The
expression level of proteins was quantitated with respect
to b-actin.
RNA isolation and northern blotting
The total cellular RNA was extracted from treated and
control HeLa cells using TRI reagent (Sigma- Aldrich,
USA) according to the manufacturer’s instruction. The
quality of RNA was estimated by electrophoresis using 2
μl of RNA solution on an ethidium bromide-stained 1%
agarose gel in 3-[N- morpholino] propane-sulfonic acid
(MOPS) buffer. Concentration of RNA was estimated
spectrophotometrically by Nanodrop (NanoDrop Tech,
USA). The probes were labeled by the random-priming
method using random primer labelling kit (Genei, Ban-
galore, India) and northern blotting was carried out.
Briefly, approximately 15 μgo fR N Aw a sr e s o l v e do n
1% agarose- MOPS formaldehyde gel. Capillary blotted
Nylon membrane (IMMOBILON-NY+, Millipore, Bed-
ford, MA) was then UV crosslinked (Hoefer UVC 500
ultraviolet crosslinker, Amersham Biosciences, England)
and washed in 6X SSC, air dried, and finally exposed in
phosphorimager (Fujifilm FLA-5100, Japan) after pre-
hybridization and hybridization in Perfect HYB-PLUS
(Sigma Inc, USA) solution as suggested by manufac-
turer’s protocol.
Results
Column chromatographic separation, thin layer
chromatography and phytochemical analysis of B. pinnata
leaf extract
Chromatographic separation of B. pinnata leaf extracts
was performed that produced a total of 6 fractions (Fig-
ure 1). Sample from each fraction was spotted on pre-
coated silica gel thin layer chromatographic plate and
eluted with chloroform: methanol (95:5) solvent system.
TLC plates were observed under visible and UV light.
Results showed presence of UV active spots in crude
extract, and fraction F1, F3 and F4 (data not shown).
The spots with UV activity were found with very low Rf
value. The phytochemical analysis of chromatographi-
cally separated fractions by Raymond’st e s tf o rc a r d i a c
glycosides and Dragendorff’s test for alkaloids were per-
formed that showed presence of alkaloids and steroidal
glycosides only in fraction F3 and F4 (Table 1). The F4
was observed to be rich in steroidal glycosides, alkaloids
and steroids and F3 gave only a faint coloration in both
the reactions. All the other fractions failed to show pre-
sence of any of these bioactive compounds.
Comparative analysis of B. pinnata and its fractions for
growth inhibitory activity against cervical cancer cells
B. pinnata crude leaf extract and all its chromatographic
fractions were examined for cell-growth inhibitory proper-
ties on HeLa cells. Cells treated with indicated concentra-
tion of test sample were examined by MTT assay for the
cell viability. Results shown in Figure 2A demonstrate pre-
sence of growth inhibitory property in crude extract and
its fraction F4 whereas fraction F3 had minor growth pro-
moting activity. Crude B. pinnata leaf extract inhibited
Table 1 Analysis of various chromatographic fraction of
B.pinnata leaf extract for presence of bioactive
phytochemicals
S. N. Test Colorimetric/
turbidity test
F1 F2 F3 F4 F5 F6
1 Raymond test (Cardiac Glycosides) - - + ++ - -
2 Dragendorff’s test (Alkaloids) - - + ++ - -
+ - Normal coloration; ++ - Dense coloration, -No change, F1 to F6 designated
chromatographic fraction of B. pinnata leaf extract.
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Page 4 of 11cervical cancer cell growth by 30% whereas fraction F4 was
comparatively more potent and inhibited cell growth by
55% at 100 μg/ml concentration (Figure 2A). On the other
hand, growth of cells treated with fraction F3 was found to
be relatively higher compared to control which was maxi-
mum (-21.3%) at 75 μg/ml. Further increase in F3 concen-
tration did not increase the growth of cervical cancer cells.
Cells treated with other fractions did not show any signifi-
cant change in their growth properties (data not shown).
Based on these preliminary observations, cells were treated
with increasing concentration of crude extracts and frac-
tion F4 for 24 h, 48 h and 72 h to examine the dose
kinetics and time course of growth inhibition. As shown
in Figure 2B and 2C, both the crude extract and fraction
F4 showed highest dose-dependent inhibition at 24 h. A
longer incubation of treated cultures resulted in partial
recovery of growth inhibition at 48 h and complete recov-
ery by 72 h. The interpolated IC50 of crude extract was
552 μg / m la n dI C 5 0o ff r a c t i o nF 4w a s9 1μg/ml in 24 h
treated cultures.
B. pinnata suppress constitutive activation of AP1 in
cervical cancer cells
To assess anti-HPV activity of B. pinnata extracts, we
next examined the effect of crude extracts and fraction
F4 on activity and expression of transcription factor
AP1. Nuclear proteins isolated from HeLa cells treated
with increasing concentration of B. pinnata crude
extract and fraction F4 were subjected to EMSA to
assess AP1’s DNA binding activity. Result in Figure 3A
show high levels of constitutively active AP1 in
untreated control cells which decreased dose-depen-
dently in cells treated with both B. pinnata crude
extracts and fraction F4. However, the crude extracts
were found to be more effective in abrogating the con-
stitutive activity of AP1 (Figure 3Aa and 3Ab). The spe-
cificity of AP1 binding was found to be specific as
nuclear extracts of untreated HeLa cells co-incubated
with cold competitor, unlabelled AP1 probe, completely
quenched the AP1 specific binding to the labeled probe
(Figure 3Ac), whereas it remained unaffected in the pre-
sence of a heterologous Oct-1 probe. Since loss of AP1
activity could be a direct result of loss of expression of
AP1 family protein that forms functional homo/hetero-
dimer of active AP1 complex, we checked the effect of
B. pinnata crude leaf extract and fraction F4 on expres-
sion of AP1 family proteins, c-Jun, JunB, JunD and c-
fos in the treated cells by immunoblotting. Results
s h o w ni nF i g u r e3 Bd e m o n s t r a t eas p e c i f i ci n h i b i t o r y
effect of crude extracts (3Ba) and fraction F4 (3Bb) on
c-Jun and c-Fos whereas treatment of HeLa cells either
by crude extract or fraction F4 did not alter expression
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Figure 2 Dose-dependent effect of B. pinnata leaf extract and
its chromatographic fraction on the viability of human cervical
cancer cells. A. HeLa cells incubated in 96 well plate without or
with indicated concentration of B. pinnata crude leaf extract or its
fraction F3 and F4 were examined for cell viability at 24 h by MTT
assay as described in Methods. Percent growth inhibition was
measured w.r.t. untreated controls. B and C. HeLa cells incubated
with increasing concentration of crude extract (B) and fraction F4
(C) were examined for cell viability at 24 h, 48 h and 72 h and their
percent viability was measured by MTT assay. The results are
representative of three independent experiments with similar
results. Values are mean ± SD of the triplicate cultures. *p < 0.05
versus untreated cultures. #p < 0.05 versus cells treated at similar
dose of crude extract or fraction F4 treatment at 48 h or 72 h
cultures.
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specific inhibition of JunD which was not significantly
altered in cells treated with crude extracts.
Anti-HPV and pro-apoptotic activity of B. pinnata fraction
F4 in cervical cancer cells
As crude extract and fraction F4 inhibited pivotal host
transcription factor AP1 in cervical cancer cells, in the
next part of the investigation, we examined effect of B.
pinnata crude extract and fraction F4 on transcription
of viral mRNA transcripts by Northern blotting using
HPV18-specific, radiolabelled probe. Results shown in
Figure 4A depict a dose-dependent decrease in the level
of HPV18 transcripts in cells treated with crude extracts
and fraction F4. Interestingly, despite having lesser cyto-
toxic activity crude extract was found to be more potent
in suppressing HPV18 expression as compared to frac-
tion F4 (Figure 4Ba and 4Bb). As cell toxicity could be
outcome of either apoptotic or necrotic death that
represents specific phytochemicals-induced programmed
cell death or non-specific cell killing respectively, we
examined the cells treated with B. pinnata fraction F4
for expression of apoptosis-associated proteins like Bax,
Bcl-2, Caspase-3 and PARP-1 by immunoblot analysis.
Results in Figure 4C demonstrate appearance of fraction
F4- induced a gradual increase in expression of proa-
poptotic Bax and elimination of anti-apoptotic protein
Bcl-2 with in 12 h. The changes in Bcl-2 and Bax
expression were accompanied by cleavage of procaspase-
3 and PARP-1 that represent hallmark features of cells
undergoing apoptotic cell death. Caspase-3 activation
and cleavage of PARP-1 were found to be late event as
they appeared by 24 h and proceeded the alteration in
Bax/Bcl-2 levels (Figure 4D).
Nuclear magnetic resonance and High performance thin
layer chromatographic analysis of fraction F4
In an effort to characterize the active principle, fraction
F4 was examined by NMR spectroscopy and compared
with other UV active fractions, F1 and F3 that served as
controls. As shown in Figure 5, NMR spectra of B. pin-
nata leaf extract, fraction F4 was rich in magnitude and
number of functional groups present on constituent
chemical entities. The NMR spectra of fraction F4 was
matched with the reported data which showed presence
of specific peaks of functional groups like δ 5.13, 4.36,
1.42 (orthoacetate), δ 10.31 (an aldehyde), δ 7.22, and
6.27 (a-pyrone), δ 4.21 (secondary hydroxyl) but at very
low intensity indicating a possibility of presence of low
concentration of bryophyllin A. Fraction F4 was further
subjected to HPTLC analysis to determine relative ratio
of different compounds within this fraction and com-
pared it with fraction F3 to classify the compounds that
are unique to F4 only. To analyze and detect com-
pounds with UV activity and terpenoidal structure the
HPTLC chromatograms of these fractions were analyzed
i nt w om o d e s ,o n e ,w i t h o u ts p r a y i n ga n yr e a g e n ta n d
visualized at 366 nm wavelength light and second,
spraying anisaldehyde sulphuric (AS) reagent and visua-
lized at 615 nm wavelength light. The HPTLC profiles
shown in Figure 6 demonstrate presence of 11 sub-
stances before and after spraying AS reagent in fraction
B
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Figure 3 Effect of B. pinnata crude leaf extract on AP1 specific
DNA-binding and expression of its constituent subunits in
cervical cancer cells. A. Nuclear proteins (10 μg/lane) of HeLa cells
treated with indicated concentrations of B. pinnata crude extracts (a)
or its fraction F4 (b) for 24 h and were assayed for AP1 DNA binding
activity by EMSA. Untreated HeLa nuclear proteins and labeled AP1
probe were incubated in the presence of 100 fold molar excess of
unlabeled homologous AP1 probe or heterologous Oct-1 probe and
assayed for AP1 specific binding by EMSA (c).F o l dc h a n g ew a s
calculated following densitometric evaluation of shifted band. B.E f f e c t
of B. pinnata leaf extracts on the expression of AP1 family proteins.
Representative immunoblots of cellular proteins isolated from HeLa
cells treated with B. pinnata c r u d el e a fe x t r a c t(a) and fraction F4 (b) as
indicated showing expression of different members of AP1 family. b-
actin served as a loading control. C.A g g r e g a t e dm e a n( ±S . D . )
abundance ratios of indicated AP1 proteins w.r.t. to b-actin following
treatment with indicated doses of crude extract and fraction F4 in
three independent experiments. Band intensity of AP1 proteins and b-
actin was measured by densitometry as described in “Methods” and
their ratio in untreated control was used as reference. *p < 0.05 versus
untreated control cultures.
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Page 6 of 11F3, and 8 & 9 substances in fraction F4 before and after
spraying AS reagent, respectively. Constituent sub-
stances were designated with numbers accordingly to
their order of relative abundance. As summarized in
Table 2 before spraying AS reagent there were 5 (sub-
stance # 2, Rf 0.91; substance # 8, Rf 0.03; substance #
18, Rf 0.06; substance # 11, Rf 0.23; & substance # 12, Rf
0.14) and 2 (substance # 9, Rf 0.12 & substance # 13, Rf
0.20) substances that were detectable were uniquely pre-
sent in fraction F3 and F4 respectively that visualized at
366 nm. Whereas after spraying the AS reagent, 4
(substance # 2, Rf 0.63; substance # 9, Rf 0.15; substance
# 10, Rf 0.56; & substance # 13, Rf 0.25) and 2 (sub-
stance # 7, Rf 0.81; & substance # 11, Rf 0.51) sub-
stances were uniquely present in fraction F3 and F4
respectively when visualized at 615 nm.
Discussion
In the present study, we extracted, purified and partially
characterized an anti-cancer and anti-HPV molecule/
compound from leaves of B. pinnata of Indian origin.
Using human cervical cancer cells in vitro examination
of B. pinnata crude extracts and its specific chromato-
graphic fractions revealed presence of a growth inhibi-
tory activity that resolved to fraction F4. Further
analysis of molecular events revealed a dose-dependent
inhibition of constitutively active AP1 by abrogating its
DNA-binding activity and expression of AP1 family pro-
teins specifically c-Jun and c-Fos, two components of
canonical functional forms of AP1. B. pinnata leaf
extract suppressed viral transcription of HPV18 in these
cervical cells in conjunction with inhibition of AP1 and
caused apoptotic cell death as revealed by appearance of
Bax, loss of Bcl-2 and cleavage of procaspase-3 to active
caspase-3 and proteolytic loss of its target PARP-1.
NMR and HPTLC analysis of fraction F4 indicated pre-
sence of alkaloids and steroidal glycosides one of which
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Figure 4 Anti-HPV and anti-cancer effect of B. pinnata crude
leaf extract and fraction F4 in cervical cancer cells. A. Northern
blot analysis of HPV18 positive HeLa cells incubated with indicated
concentrations of crude leaf extract and fraction F4. Quantity and
quality of total RNA (15 μg/lane) extracted was examined on
agarose gel by assessing 28S & 18S ribosomal RNAs (upper panels).
The membranes were hybridized with HPV18-specific probe (middle
panel), stripped and rehybridized with b-actin -specific DNA probe
as an internal control to assess equal loading (lower panels). B.
Aggregated mean (± S.D.) abundance ratio of HPV18 transcript w.r.t.
to b-actin following treatment with indicated doses of crude extract
(a) and fraction F4 (b) in three independent experiments. The
abundance ratio HPV18 transcript to b-actin mRNA was analyzed by
densitometry as described in “Methods” and their ratio in untreated
control was used as reference. C. Immunoblotting analysis of Bcl-2,
and Bax, caspase-3, poly (ADP-ribose) polymerase-1 (PARP- 1), in
fraction F4 treated HeLa cells at different time-intervals. D. The
abundance ratio of indicated proteins to b-actin was analyzed by
densitometry and their ratio in untreated control was used as
reference. The values indicate aggregated mean ± S.D. of three
independent experiments. *p < 0.05 versus untreated control
cultures.
A
B
C
Fraction F1
Fraction F3
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Figure 5 Functional group analysis of UV active B. pinnata
fractions by Proton NMR. Fraction F1, F3 and F4 were dissolved in
CDCl3 and NMR was taken at 400 MHz.
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Page 7 of 11could be bryophyllin A. The chloroform-based extrac-
tion procedure used in the present study has been routi-
nely followed by several other studies exploring
therapeutic phytochemical [31]. The procedure focused
primarily on the chloroform-extracted fraction only and
the activity, if any, in the aqueous phase was intentially
left out as the same could be potentially contaminating
for cell culture as they are likely to possess bacteria and
fungal spores and hence could have interfered with the
assay. However earlier studies show presence of cyto-
toxic activities such as bryophyllin B that converges in
aqueous phase [31] and could prove useful. Therefore,
more refined extraction method are needed to resolve
the anti-cancer activity by examining the extract without
separation with chloroform as demonstrated by some of
the investigators [32] and will be considered in future
studies.
A dose-dependent cytotoxic activity observed in leaf
extract and its fraction F4 demonstrates a potential ther-
apeutic utility of this medicinal plant against cervical
cancer. Earlier studies by Yamagishi et al. 1989 demon-
strated presence of similar cytotoxic activity against KB
cells in methanolic extracts of B. pinnata [31]. Addition-
ally, antitumor activity of B. pinnata leaves owing to its
antimutagenic activity has also been demonstrated [32].
Interestingly, comparative analysis of fractionated crude
leaf extracts in our experiments revealed cytotoxic activ-
ity that specifically resolved in pet ether: eth acet::50:50.
Earlier studies also show that antimutagenic activity can
be extracted in pet ether and ethyl acetate [32]. How-
ever, the IC50 value derived from HPLC purified active
principles from chloroform extracted B. pinnata plant in
earlier studies [31] were much lower (ranged between
10hg/ml-4 μg/ml) compared to the one isolated in cur-
rent study (91 μg/ml). This may be partly due to incom-
plete separation, but the variability of sensitivity of the
cell line used in present study, could also be a major
contributor. As a general notion, HeLa cells are much
more resistant than many cell lines. Therefore, further
studies are warranted on a panel of cell lines to verify
the anti-cancer potential of fraction F4. Moreover, the
inhibitory effect of both crude extract and fraction F4
were maximal at 24 h but declined thereafter. These
observations suggest that active principle might get
metabolized or get inactivated during culture process
and is no more available to impose growth inhibitory
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Fraction F4
Rf  Value  Assigned Substance  Area % 
0.00 Substance  5  02.66 
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0.37 Substance  7  01.40 
0.54 Substance  4  05.16 
0.62 Substance  3  13.58 
0.71 Substance  6  01.29 
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0.25 Substance  13  00.83 
0.36 Substance  5  07.22 
0.56 Substance  10  02.86 
0.63 Substance  2  26.16 
0.73 Substance  3  04.37 
0.79 Substance  4  11.13 
0.88 Substance  1  41.78 
Rf  Value Assigned Substance  Area %
0.01 Substance  5  07.96 
0.12 Substance  9  02.91 
0.20 Substance  13  03.95 
0.35 Substance  7  07.43 
0.51 Substance  4  06.69 
0.61 Substance  3  08.79 
0.72 Substance  6  00.96 
0.88 Substance  1  61.31 
Rf Value Assigned Substance  Area %
0.02 Substance  6  04.56 
0.12 Substance  8  05.39 
0.20 Substance  12  04.21 
0.36 Substance  5  07.16 
0.51 Substance  11  01.80 
0.63 Substance  2  27.84 
0.74 Substance  4  03.02 
0.81 Substance  7  08.68 
0.89 Substance  1  37.33 
After spraying anisaldehyde sulphuric acid reagent
Figure 6 HPTLC profiling of B. pinnata leaf extract, fraction F3
and F4 (A) Finger printing of B. pinnata leaf extract, fraction F3
and F4 before and after spraying anisaldehyde sulphuric acid
reagent at UV (366 nm) and visible (615 nm) light. Tables
represent Rf value of the detectable substances in fractions with
their relative content. Constituent substances were designated with
numbers accordingly to their decreasing order of relative
abundance.
Table 2 Analysis for presence of unique substances in fraction F3 and F4 before and after spraying anisaldehyde
sulphuric acid reagent
Before Spraying After Spraying Anisaldehyde Sulphuric Acid Reagent
S.N Substance Rf value F3 F4 Substance Rf value F3 F4
1 Substance 2 0.91 + - Substance 2 0.63 + -
2 Substance 8 0.03 + - Substance 7 0.81 - +
3 Substance 9 0.12 - + Substance 9 0.15 + -
4 Substance 10 0.06 + - Substance 10 0.56 + -
5 Substance 11 0.23 + - Substance 11 0.51 - +
6 Substance 12 0.14 + - Substance 13 0.25 + -
7 Substance 13 0.20 - + - - -
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Page 8 of 11effect. However, these assumptions need further
investigation.
In contrast to fraction F4, fraction F3 showed a minor
growth promoting activity in dose range 50-100 μg/ml.
These results, suggest accumulation of cell growth pro-
moters in F3 fraction that may have coexisted in the
plant leaves along with cytotoxic activity. However,
there is no report which specifically describes any tumor
growth promoting activity associated with this plant.
Our results indicated that B. pinnata leaf extracts and
its fraction F4 specifically inhibited URR-directed gene
expression of HPV18. Constitutively active AP1 by itself
has oncogenic outcome because of its regulatory role in
several cellular processes like inflammation [33]. More-
over, AP1 is also essentially required for the mainte-
nance of HPV expression through cis-acting binding
sites on URR of HPV18. In contrast to higher cytotoxi-
city potential revealed by fraction F4, the EMSA per-
formed in the present study for assessment of AP1
DNA- binding activity revealed a stronger inhibition of
AP1 activity by crude extracts as compared to more
cytotoxic fraction F4. Similarly, the inhibition of viral
transcription of HPV18 was lesser in cells treated with
fraction F4 which was considered to have higher con-
centration of active principle. These results suggest that
fraction F4 of B. pinnata leaf extracts might possess two
distinct activities which apart from inhibiting activity of
transcription factors like AP1 that are responsible for
expression of viral oncoproteins (E6 & E7) through
binding to URR resulting in oncogenic cell division, can
independently prevent cell growth of cancer cells by
alternate mechanism(s). This assumption get strength
from the finding that cells treated with fraction F4,
unlike crude extract, had strongly reduced JunD levels
along with reduced c-Jun and c-Fos. Such changes in
components of AP1 complex may have varied implica-
tion in cellular context and the same could have been
translated in higher cytotoxic potential of fraction F4
despite affecting HPV18 transcription at lesser level.
Results of present investigation indicated that cells
treated with B. pinnata extracts undergo phytochemical-
specific programmed cell death/apoptosis and did not
induce non-specific necrotic death. A time-dependent
appearance of pro-apototic Bax and loss of anti-apopto-
tic Bcl-2 along with caspase-3 activation and PARP-1
cleavage over 24 h time period strongly supported this
assumption. Like, majority of cytotoxic phytochemicals,
B. pinnata induced apoptotic cell death via intrinsic
pathway through loss of mitochondrial membrane
potential that are known to be accompanied by Bax
expression and loss of Bcl-2 [28,34-36].
In an effort to characterize the active principle
through NMR and HPTLC our study revealed that one
of the cardiac glycoside that converge in fraction F4
could be bryophyllin-A. However, the study showed pre-
sence of high levels of alkaloid that also converge to
fraction F4. A number of bioactive molecules including
flavanoids, glycosides, steroids, bufadienolides and
organic acids have been identified in several studies
[10,11,37]. Interestingly, one of the flavanoid glycoside,
quercetin analog Quercitrin (quercetin 3- O-alpha- L-
rhamnopyranoside) and skapinnatoside, has been shown
in several studies to possess anti-leishmanial and anti-
inflammatory activities [8,15,38]. In addition, Bufadieno-
lides, bryophyllin-A, -B, -C and bersaldegenin-1, 3, 5-
orthoacetate were isolated from the plant of Taiwan ori-
gin and was shown to possess hepato-protective activity
and cytotoxicity [31,39-41,31]. Apart from this bryophyl-
lol, bryophollone, bryophollenone, bryophynol, 2(9-dece-
nyl) phenenthrene (I), 2(undecenyl) phenenthrene (II),
18a-oleanane, ψ-taraxasterol, a-and b-amyrins and their
acetates, 24-epiclerosterol [24(R) stigmasta-5, 25-dien-
3b-ol], 24(R) 5a-stigmasta-7, 25-dien-3b-ol, 5a-stig-
mast-24-en-3b-ol and 25-methyl-5a-ergost-24(28)-en-
3b-ol were isolated from the plant leaves and other aer-
ial parts [42,43]. Therefore, it is difficult to conclude
from the present study that anti-HPV/anticancer activity
observed in crude leaf extract or fraction F4 is displayed
specifically by any single chemical entity. Though in
unrelated experimental model of EBV-early antigen acti-
vation in Raji cells, among 5 different bufadienolides iso-
lated from kalanchoe pinnata, showed anti-tumor
promoting activity [40] and among them bryophyllin A
was found to possess strongest activity. In another
study, three new compounds, kalanchosides A-C, as well
as five known compounds, were isolated from the aerial
parts of Kalanchoe gracilis, where all eight isolated com-
pounds showed significant cytotoxic activity against a
panel of human tumor cell lines. However, only one of
the known compound bryophyllin B inhibited HIV repli-
cation in H9 lymphocyte cells [44].
Conclusion
Our study indicates for the first time that B. pinnata
can act as an anti-HPV molecule and apoptosis- indu-
cing property. It therefore provides an important lead
for development of anti-cancer therapeutics for manage-
ment of cervical cancer. Further analysis and purifica-
tion of the B. pinnata leaf extract and in vivo studies
may help in discovering the full potential of B. pinnata
as a source of an effective antiviral/anti-cancer drug.
Acknowledgements
This work was supported by the funds from Indian Council of Medical
Research (ICMR), and Department of Biotechnology, Government of India (to
A.C.B and B.C.D). The authors thank Dr. Sayeed, Lecturer, Dept of
Pharmacognosy and Phytochemistry, Jamia Hamdard, New Delhi, for
immense help in biochemical and HPTLC analysis.
Mahata et al. BMC Complementary and Alternative Medicine 2012, 12:15
http://www.biomedcentral.com/1472-6882/12/15
Page 9 of 11Author details
1Division of Molecular Oncology, Institute of Cytology and Preventive
Oncology (ICMR), I-7, Sector-39, Noida 201301, INDIA.
2Department of
Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore 560
012, INDIA.
3Dr. B.R Ambedkar Centre for Biomedical Research, University of
Delhi (North Campus), Delhi 110007, INDIA.
Authors’ contributions
S Mahata and S Maru contributed equally to this work. S Mahata and S Maru
designed methods and experiments, carried out the laboratory experiments,
analyzed the data, interpreted the results and wrote the paper. SS and AP
co-worked on western blotting experiments and their interpretation. GM
designed and worked on NMR experiments. ACB and BCD defined the
research theme, discussed analysis, interpretation, and presentation. All
contributing authors seen and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 November 2011 Accepted: 10 March 2012
Published: 10 March 2012
References
1. Tan G, Gyllenhaal C, Soejarto DD: Biodiversity as a source of anticancer
drugs. Curr Drug Targets 2006, 7(3):265-277.
2. Akinpelu DA: Antimicrobial activity of Bryophyllum pinnatum leaves.
Fitoterapia 2000, 71(2):193-194.
3. Misra SaD SN: Antifungal activity of leaf extract of some higher plants.
Acta Botanica Indica 1979, 7:147-150.
4. Pal S, Nag Chaudhuri AK: Studies on the anti-ulcer activity of a
Bryophyllum pinnatum leaf extract in experimental animals. J
Ethnopharmacol 1991, 33(1-2):97-102.
5. Pal S, Nag Chaudhuri AK: Preliminary studies on the anti-inflammatory
and analgesic activities of bryophyllum pinnatum (Lam.). Med Sci Res
1989, 17:561-562.
6. Pal S, Nag Chaudhuri AK: Further studies on the anti-inflammatory profile
of the methanolic fraction of the fresh leaf extract of bryophyllum
pinnatum. Fitoterapia 1992, 63:451-459.
7. Ojewole JAO: Antihypertensive properties of bryophyllum pinnatum
(Clam; oken) leaf extracts. Am J Hypert 2002, 15(4):A34-A39.
8. Ojewole JA: Antinociceptive, anti-inflammatory and antidiabetic effects
of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. J
Ethnopharmacol 2005, 99(1):13-19.
9. Umbuzeiro-Valent G, Roubicek DA, Haebisch EM: Mutagenic and
antimutagenic evaluation of the juice of the leaves of Bryophyllum
calycinum (Kalanchoe pinnata), a plant with antihistamine activity.
Environ Mol Mutagen 1999, 33(4):325-327.
10. Gaind KN, Gupta RL: Flavonoid glycosides from Kalanchoe pinnata. Planta
Med 1971, 20(4):368-373.
11. Marriage PB, Wilson DG: Analysis of the organic acids of Bryophyllum
calycinum. Can J Biochem 1971, 49(3):282-296.
12. Muzitano MF, Falcao CA, Cruz EA, Bergonzi MC, Bilia AR, Vincieri FF, Rossi-
Bergmann B, Costa SS: Oral metabolism and efficacy of Kalanchoe
pinnata flavonoids in a murine model of cutaneous leishmaniasis. Planta
Med 2009, 75(4):307-311.
13. Muzitano MF, Tinoco LW, Guette C, Kaiser CR, Rossi-Bergmann B, Costa SS:
The antileishmanial activity assessment of unusual flavonoids from
Kalanchoe pinnata. Phytochemistry 2006, 67(18):2071-2077.
14. Torres-Santos EC, Da Silva SA, Costa SS, Santos AP, Almeida AP, Rossi-
Bergmann B: Toxicological analysis and effectiveness of oral Kalanchoe
pinnata on a human case of cutaneous leishmaniasis. Phytother Res 2003,
17(7):801-803.
15. Muzitano MF, Cruz EA, de Almeida AP, Da Silva SA, Kaiser CR, Guette C,
Rossi-Bergmann B, Costa SS: Quercitrin: an antileishmanial flavonoid
glycoside from Kalanchoe pinnata. Planta Med 2006, 72(1):81-83.
16. Da-Silva SA, Costa SS, Rossi-Bergmann B: The anti-leishmanial effect of
Kalanchoe is mediated by nitric oxide intermediates. Parasitology 1999,
118(Pt 6):575-582.
17. Cao H, Xia J, Xu D, Lu B, Chen G: The separation and identification of the
flavonoids from the leaves of Bryophyllum pinnatum. Zhong Yao Cai
2005, 28(11):988-990.
18. Parkin DM: The global health burden of infection-associated cancers in
the year 2002. Int J Cancer 2006, 118(12):3030-3044.
19. Durst M, Gissmann L, Ikenberg H, zur Hausen H: A papillomavirus DNA
from a cervical carcinoma and its prevalence in cancer biopsy samples
from different geographic regions. Proc Natl Acad Sci USA 1983,
80(12):3812-3815.
20. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur
Hausen H: A new type of papillomavirus DNA, its presence in genital
cancer biopsies and in cell lines derived from cervical cancer. EMBO J
1984, 3(5):1151-1157.
21. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell
control in early events in carcinogenesis. J Natl Cancer Inst 2000,
92(9):690-698.
22. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, Hsieh CY,
Liaw KL, Hsing AW, Chen CJ: Persistence of type-specific human
papillomavirus infection and increased long-term risk of cervical cancer.
J Natl Cancer Inst 2011, 103(18):1387-1396.
23. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002, 2(5):342-350.
24. Satoru Kyo DJK, Masaki Inoue, Taro Kanaya, Laimins ALaimonis: Expression
of AP1 during cellular differentiation determines human papillomavirus
E6/E7 expression in stratified epithelial cells. J Gen Virol 1997, 78:401-411.
25. Butz K, Hoppe-Seyler F: Transcriptional control of human papillomavirus
(HPV) oncogene expression: composition of the HPV type 18 upstream
regulatory region. J Virol 1993, 67(11):6476-6486.
26. Prusty BK, Das BC: Constitutive activation of transcription factor AP-1 in
cervical cancer and suppression of human papillomavirus (HPV)
transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer
2005, 113(6):951-960.
27. Bharti AC, Shukla S, Mahata S, Hedau S, Das BC: Anti-human
papillomavirus therapeutics: facts & future. Indian J Med Res 2009,
130(3):296-310.
28. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC: Berberine
modulates AP-1 activity to suppress HPV transcription and downstream
signaling to induce growth arrest and apoptosis in cervical cancer cells.
Mol Cancer 2011, 10:39.
29. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V,
Bhambhani S, Roy M, Batra S, et al: Elimination of high-risk human
papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in
women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol
2009, 135(12):1701-1709.
30. Zhengyin Yan GC: Evaluation of cytochrome P450 inhibition in human
liver microsomes. In Optimization in drug discovery: in vitro methods. Edited
by: Zhengyin Yan GWC. Totowa, NJ: Humana press; 2004:231-244.
31. Yamagishi T, Haruna M, Yan XZ, Chang JJ, Lee KH: Antitumor agents, 110.
Bryophyllin B, a novel potent cytotoxic bufadienolide from Bryophyllum
pinnatum. J Nat Prod 1989, 52(5):1071-1079.
32. Emmanuel E, Obaseiki-Ebor KO, Telikepalli Hannumaiah, Mitscher Lester A,
Delbert M: Shankel: Antimutagenic activity of extracts of leaves of four
common edible vegetable plants in Nigeria (West Africa). Mutat Res Lett
1993, 302(2):109-117.
33. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev
Cancer 2003, 3(11):859-868.
34. el SA Arafa, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, El-Mahdy MA,
Wani AA: Thymoquinone up-regulates PTEN expression and induces
apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res
2011, 706(1-2):28-35.
35. Bharti AC, Donato N, Singh S, Aggarwal BB: Curcumin (diferuloylmethane)
down-regulates the constitutive activation of nuclear factor-kappa B and
IkappaBalpha kinase in human multiple myeloma cells, leading to
suppression of proliferation and induction of apoptosis. Blood 2003,
101(3):1053-1062.
36. Halder B, Bhattacharya U, Mukhopadhyay S, Giri AK: Molecular mechanism
of black tea polyphenols induced apoptosis in human skin cancer cells:
involvement of Bax translocation and mitochondria mediated death
cascade. Carcinogenesis 2008, 29(1):129-138.
37. El Abdellaoui S, Destandau E, Toribio A, Elfakir C, Lafosse M, Renimel I,
Andre P, Cancellieri P, Landemarre L: Bioactive molecules in Kalanchoe
pinnata leaves: extraction, purification, and identification. Anal Bioanal
Chem 2010, 398(3):1329-1338.
Mahata et al. BMC Complementary and Alternative Medicine 2012, 12:15
http://www.biomedcentral.com/1472-6882/12/15
Page 10 of 1138. Anjoo Kamboj aAKS: Bryophyllum pinnatum (Lam.) Kurz.: Phytochemical
and pharmacological profile: A review. Pharmacognosy Rev 2009,
3(6):364-374.
39. Yamagishi T, Yan XZ, Wu RY, McPhail DR, McPhail AT, Lee KH: Structure
and stereochemistry of bryophyllin-A, a novel potent cytotoxic
bufadienolide orthoacetate from Bryophyllum pinnatum. Chem Pharm
Bull(Tokyo) 1988, 36(4):1615-1617.
40. Supratman U, Fujita T, Akiyama K, Hayashi H: New insecticidal
bufadienolide, bryophyllin C, from Kalanchoe pinnata. Biosci Biotechnol
Biochem 2000, 64(6):1310-1312.
41. Supratman U, Fujita T, Akiyama K, Hayashi H, Murakami A, Sakai H,
Koshimizu K, Ohigashi H: Anti-tumor promoting activity of bufadienolides
from Kalanchoe pinnata and K. daigremontiana x tubiflora. Biosci
Biotechnol Biochem 2001, 65(4):947-949.
42. Toshihiro Akihisa WCMCK, Tamura Toshitake, Matsumoto Taro: Sterols
ofKalanchoe pinnata: First report of the isolation of both C-24 epimers
of 24-alkyl-Δ25-sterols from a higher plant. Lipids 1991, 26(8):660-665.
43. Salimuzzaman Siddiqui SF, Siddiqui Bina S, Naheed Sultana: Triterpenoids
and phenanthrenes from leaves of Bryophyllum pinnatum.
Phytochemistry 1989, 28(9):2433-2438.
44. Wu PL, Hsu YL, Wu TS, Bastow KF, Lee KH: Kalanchosides A-C, new
cytotoxic bufadienolides from the aerial parts of Kalanchoe gracilis. Org
Lett 2006, 8(23):5207-5210.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/12/15/prepub
doi:10.1186/1472-6882-12-15
Cite this article as: Mahata et al.: Anticancer property of Bryophyllum
pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC
Complementary and Alternative Medicine 2012 12:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mahata et al. BMC Complementary and Alternative Medicine 2012, 12:15
http://www.biomedcentral.com/1472-6882/12/15
Page 11 of 11